Press Releases July 28, 2026 04:05 PM

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference

PacBio to present at Canaccord Genuity 46th Annual Growth Conference with live webcast access

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
PACB

Pacific Biosciences (PacBio) announced its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event will feature discussions on the company's advanced sequencing technologies and their applications in life sciences. A live webcast and replay will be available for investors and interested parties.

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
PACB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PacBio management to speak at a major growth conference highlighting company technology and strategy.
  • The company focuses on high-quality long-read sequencing solutions spanning multiple research applications including human genetics, oncology, and microbiology.
  • Live webcast and replay increase accessibility for investors and stakeholders to gain insights into PacBio’s business outlook.

MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts.

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:
ir@pacb.com

Media:
pr@pacb.com


Risks

  • Market adoption of PacBio's sequencing technologies may face competition or slower growth affecting long-term revenue.
  • Dependence on research and development success to maintain technological leadership in sequencing solutions.
  • The bioinformatics and life sciences sectors are impacted by technological advancements and funding availability, which influence PacBio's market performance.

More from Press Releases

MISSION SUCCESS: Rocket Lab Launches 96th Electron Mission Sep 19, 2026 FortuneX Acquisition Corporation and WT Realty Group Inc. Announce Business Combination Agreement Sep 18, 2026 XAI Floating Rate & Alternative Income Trust Announces Commencement of Tender Offer Sep 18, 2026 Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States Sep 18, 2026 Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking Sep 18, 2026